After a hiatus, Alacrita is making a return to Twitter! We often discuss #pharmavaluations, #pharmadd, #duediligence, #biotechnology, and #pharmaindustry. Here we dive into the significance of what assumptions go into a valuation. alacrita.com/blog/whats-the…

Did you know, Alacrita's experts have conducted over 200 due diligences for large pharma, biotech, universities, and investors? This is underpinned by our ability to draw in functional specialists across all domains of healthcare R&D. Learn more at lnkd.in/d2C2c6rm

There is good reason to be excited about #GeneTherapy and #Celltherapy in 2023, but a number of challenges still remain for businesses. Alacrita capitalizes on its extensive expert network to serve the needs of companies in this space. See for yourself! alacrita.com/case-studies/t…

We receive a steady stream of inquiries about drug repurposing, often seeking a low-risk opportunity with a large upside. Often though, the closer you get, the less attractive a proposition seems. In general, there’s less repurposing than some may think. alacrita.com/blog/drug-repu…

Just like cancer vaccines, researchers have targeted the Warburg effect as the basis for cancer therapy. After the latest clinical trial failure, maybe it's time for a time out? nature.com/articles/s4159…

Bringing on a CMO is a major commitment that takes significant time. Our CMO consultants can provide interim support and bring the expertise to keep your pipeline on track, as well as represent you with regulators and investors. Reach out if interested alacrita.com/interim-chief-…

With the recent reporting of positive early clinical data for two major cancer vaccines, has the mRNA approach finally provided the breakthrough we needed? Our latest piece analyzes the proposition.alacrita.com/blog/cancer-va…

CAR-T technologies are advancing and showing signs of overcoming the initial limitations we outlined 7 (!) years ago in Commercialization of Cellular Immunotherapies (Biochem. Soc. Trans., 2016). CRISPR and synthetic biology look very promising. #CRISPR nature.com/articles/d4158…

With new, proposed guidance showing clear preference for RCTs, is the FDA decelerating the Accelerated Approval process for oncology drugs?alacrita.com/blog/maybe-the…

Alacrita is pleased to announce the promotion of Saadia Basharat, PhD, to Head of West Coast Consulting! To better serve our growing client base in the western United States and Asia, she will provide support from San Diego. Learn more:alacrita.com/news/alacrita-…

Experts have expertise, but the ideal expert witness brings more to the task. Having these qualities can make a crucial difference in their contribution to any life science legal case. Read more: alacrita.com/blog/experts-a…

Cancer chemotherapy may have fallen out of fashion, but perhaps prematurely. Amidst the landscape are several high potential opportunities worthy of big pharma & investor interest. Read more:alacrita.com/whitepapers/ne…

Biotech has seen a lot of activity in the cell and gene therapy space as of late with more on the horizon. Alacrita's Eugene Mironets gives an update on the most current clinical iPSC developments. Exciting times ahead! #cellandgenetherapy #biotech #ipsc alacrita.com/whitepapers/th…

Alacrita is excited to work with Ensysce in their efforts to partner and license their abuse deterrent technology platform and assets. ir.ensysce.com/news/press-rel…

If you are a life science company or institution in need of BD, commercialization support, or even expert witness placement, Alacrita can help. See for yourself in our case study database. alacrita.com/case-studies

For biotechs developing an asset for partnering, it’s important to consider the key deal-success ingredients, in the eyes of a future pharma partner, well in advance. It’s never too early to start, and doing so can have a dramatic effect on your outcome. alacrita.com/blog/pharma-pa…

With an increasing number of projects in the human longevity space this is an interesting article discussing the continued challenges and possible routes forward in generating clinical PoC in this field. sciencedirect.com/science/articl…

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies? lnkd.in/eUqua9k